

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Leukemia	Myeloid-lymphoid or mixed-lineage leukemia (MLL; HRX); multiple endocrine neoplasia I (MEN1; Menin)	<p><i>In vitro</i> studies identified thienopyrimidine-based MEN1 inhibitors that could help treat leukemias. In a panel of human MLL cell lines, inhibitors that blocked the interaction between MEN1 and MLL decreased cell proliferation and expression of target genes and increased apoptosis compared with vehicle. Ongoing studies include developing more potent compounds that will be tested in animal models of MLL.</p> <p><b>SciBX 5(6); doi:10.1038/scibx.2012.148</b> Published online Feb. 9, 2012</p>	Patent application filed; available for licensing	<p>Grembecka, J. <i>et al. Nat. Chem. Biol.</i>; published online Jan. 29, 2012; doi:10.1038/nchembio.773</p> <p><b>Contact:</b> Tomasz Cierpicki, University of Michigan, Ann Arbor, Mich. e-mail: <a href="mailto:tomaszc@umich.edu">tomaszc@umich.edu</a></p> <p><b>Contact:</b> Jolanta Grembecka, same affiliation as above e-mail: <a href="mailto:jolantag@umich.edu">jolantag@umich.edu</a></p>